The global omics-based clinical trials market size was valued at USD 25.2 billion in 2020, and is predicted to be worth around USD 50.5 billion by 2030, registering a CAGR of 6.4% during the forecast period 2022 to 2030.
Omics has turned out to be the most advanced approach in molecular research. It includes all the field of biological sciences that ends with the suffix - omics. Various disciplines can be classified as omics such as proteomics, genomics, transcriptomics, and metabolomics. The outbreak of coronavirus accelerated the adoption of new approaches, models, and technology in clinical trials, this has positively impacted market growth.
The demand is growing for a pattern shift toward the stratification of patients or even personalized medicine. There are several complex diseases that urgently need a better understanding of their analysis and more effective therapeutic strategies. Currently, omics-based studies make the majority of precision medicine-based data, e.g. DNA sequencing technique is already being used to identify genetic material that enhances specific cancers.
|Market Size||US$ 50.5 billion by 2030|
|Growth Rate||CAGR of 6.4% From 2022 to 2030|
|Largest Market||North America|
|Forecast Period||2022 to 2030|
|Segments Covered||Phase, Study design, Indication|
|Regional Scope||North America, Europe, Asia Pacific, Latin America, Middle East & Africa|
|Companies Mentioned||Parexel International Corporation; Pharmaceutical Product Development (PPD); Charles River Laboratory, ICON plc, SGS SA; Eli Lilly and Company; Pfizer Inc.; Covance Inc.; Novo Nordisk; Rebus Bio|
By Phase Analysis
The phase II segment dominated the market for omics-based clinical trials and accounted for the largest revenue share of 37.8% in 2021. The segment is expected to witness a CAGR of 7.1% over the forecast period.
Phase II clinical trials had the highest number of projects in 2020 and this trend is expected to grow further owing to increasing investments in R&D by industry and non-industry sponsors.
By Study Design Analysis
The interventional studies segment dominated the market for omics-based clinical trials and accounted for the largest revenue share of 78.3% in 2021.
The segment is expected to exhibit a CAGR of 7.1% over the forecast period owing to the increasing number of interventional designs of clinical trials. Interventional studies are categorized based on the intervention that is to be studied which includes drug or biologic, surgical procedure, behavioral, and devices.
The expanded access studies segment is anticipated to witness a lucrative CAGR of 8.6% during the forecast period. Interventional study designs are known to provide the most reliable data in epidemiological research in genomics or any other omics-based studies.
By Indication Analysis
The oncology segment dominated the market for omics-based clinical trials and accounted for the largest revenue share of 46.7% in 2021. The segment is expected to witness a CAGR of 7.6% during the forecast period.
The worldwide cancer cases are projected to grow by 50% and worldwide cancer deaths are expected to rise by 60% till 2030 which indicates growing potential for the omics-based clinical trial in this segment.
The research on cardiology is ideally positioned to address the epidemic of noninfectious causes of death, as well as advance the understanding of human health and disease, through the development and implementation of precision medicine.
By Regional Analysis
North America dominated the market for omics-based clinical trials and held the largest revenue share of 43.6% in 2021. This can be attributed to the huge R&D investments, the presence of global players, and their efforts to come up with newer patents.
Asia Pacific is the fastest growing market as many developed nations are investing in Asia-Pacific regions. Besides, the recruitment for clinical trials is increasing in Asia as compared to North America, and Europe. This is due to the large patient pool and low trial cost.
Parexel International Corporation
Pharmaceutical Product Development (PPD)
Charles River Laboratory
Eli Lilly and Company
By Study Design
Expanded Access Studies
Genetic Diseases (includes the rare diseases)
Others (includes ophthalmic, ear diseases, etc)
Middle East & Africa
The omics-based clinical trials market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of omics-based clinical trials market for the base year 2021 and the forecast between 2022 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global omics-based clinical trials market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the omics-based clinical trials market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted omics-based clinical trials market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the omics-based clinical trials capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of omics-based clinical trials by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global omics-based clinical trials market. These figures have been provided in terms of both revenue and volume for the period 2019 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major omics-based clinical trials market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of omics-based clinical trials market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the omics-based clinical trials industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
omics-based clinical trials market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to omics-based clinical trials market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of omics-based clinical trials market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new omics-based clinical trials market. These factors have benefited the growth of the global market for omics-based clinical trials. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for omics-based clinical trials. The global market is segmented on the basis of region, application, end-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of omics-based clinical trials are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
The study objectives of this report are:
Cancer Supportive Care Drugs Market (By Therapeutic Class: G-CSFs, Anti-emetics, ESAs, Bisphosphonates, Opioids, NSAIDs & Others)- Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...
eHealth Devices Market( By Type: Blood Pressure Meters, Fever Meters, Glucose Meters, Care Phone/Social Alarms)- Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...
Tracheostomy Products Market (By Demographics: Adults, Paediatrics/Neonatal; By Type: Tracheostomy Tubes, Ventilation Accessories ; By End Use: Hospitals & Surgery Centers, Ambulatory Care Centers, Home Care Settings, Others; By Technique) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...
Smart Blood Pressure Monitoring Devices Market (By Type: Upper Arm Blood Pressure Monitor, Wrist Blood Pressure Monitor Finger Blood Pressure Monitor; By Technology: Wi-Fi Based/4G, Bluetooth Based)- Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...
Laparoscopic Electrodes Market (By Application: Bariatric, General Surgeries; By Product: Monopolar, Bipolar Electrodes; By End User: Hospital, Ambulatory)- Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030Read more...